Randomized Study of Circulating Tumor DNA to Guide Treatment Monitoring in Advanced Non-Small Cell Lung Cancer
Led by Zealand University Hospital · Updated on 2026-01-09
350
Participants Needed
5
Research Sites
261 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of liquid biopsy monitoring through circulating tumor DNA ctDNA in patients with advanced non-small cell lung cancer NSCLC who are receiving immunotherapy. This study aims to improve treatment monitoring by reducing ineffective treatments and unnecessary side effects, while also exploring the cost-effectiveness of incorporating liquid biopsy into routine care. It is a prospective randomized interventional study involving multiple clinical oncology departments and led by Zealand University Hospital.
Participants are assigned to one of two groups one group will have their treatment monitored using longitudinal ctDNA measurements along with Quality of Life assessments, while the other group will receive standard monitoring through regular CT scans and Quality of Life assessments. In the ctDNA group, treatment may be discontinued earlier than the usual two-year immunotherapy duration if a complete molecular response is detected in plasma, potentially shortening treatment periods for some patients.
During the study, patients will undergo regular evaluations that include quality of life assessments, monitoring for adverse events, and tracking the number of treatments received until disease progression. The main outcome measured is overall survival over an average follow-up of three years. Secondary outcomes include physician assessments of quality of life, adverse event recording, treatment frequency, and health cost-utility analysis. The total participation time is approximately three years, during which researchers will assess the clinical benefit and economic impact of ctDNA-guided treatment monitoring.
CONDITIONS
Brief Title
Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Newly diagnosed, histologically confirmed Non-Small Cell Lung Cancer (NSCLC)
Advanced or locally advanced disease without curative treatment options
Age over 18 years
Performance Status score of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
Measurable disease according to iRECIST criteria version 1.1
Eligible for first line immunotherapy (monotherapy)
Signed informed consent
You will not qualify if you...
Presence of targetable genetic alterations in EGFR, ALK, or ROS-1
Having other active cancers
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 2 years of immunotherapy or until treatment discontinuation based on monitoring results
Participants receive first line immunotherapy monitored by either circulating tumor DNA measurements or CT scans, with assessments of treatment efficacy and quality of life.
Regular visits for treatment and monitoring during immunotherapy
Follow-up
Duration - Up to 3 years from study enrollment
Participants are followed for overall survival and long-term outcomes after treatment completion or discontinuation.
Periodic visits for survival and health assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of OM-RCA-01 Antibody for Safety and Effectiveness in Treating Metastatic Cancers with FGFR1
Randomized Study Comparing PF-08046054 Versus Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer
Phase 3 Study of Armatinib Alone or With Stereotactic Radiotherapy for EGFR-mutated Non-small Cell Lung Cancer Brain Metastases
Phase II Study of Befotertinib and Icotinib as First Treatment for Adults With Advanced or Metastatic Non-Small Cell Lung Cancer Having Rare EGFR Mutations
Randomized Study of Circulating Tumor DNA to Guide Treatment Monitoring in Advanced Non-Small Cell Lung Cancer
National Clinical Research Platform Assessing Molecular Testing, Treatment, and Outcomes in Non-Small and Small Cell Lung Cancer Patients
Study of Lazertinib Plus Tepotinib in Patients with EGFR Mutated Non-Small Cell Lung Cancer and MET Amplification After Progression on Lazertinib
Proteomic-Guided Risk-Adapted Systemic Therapy Versus Standard Care in Untreated Advanced Non-Small Cell Lung Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
ctDNA guided immunotherapy in patients with advanced non-small cell lung cancer: a nationwide Danish, randomised, intervention study (PRELUCA-PRediction in LUng CAncer Treatment) - study protocol.
Michael Elmkvist Andersen, Christa Haugaard Nyhus, Weronika Maria Szejniuk...